LGX818

LGX818
Clinical data
ATC code None
Legal status
Legal status
  • Investigational
Identifiers
ChemSpider 28536139
Chemical and physical data
Formula C22H27ClFN7O4S
Molar mass 540.011 g/mol
3D model (Jmol) Interactive image

Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.[1][2][3]

It is a Selective BRAF Inhibitor,[4] and is in phase III clinical trials.

Clinical trials

Several clinical trials of LGX818, either alone or in combinations with the MEK inhibitor MEK162,[5] CDK4 inhibitor LEE011[6] are being run. The initial results are encouraging[4] and were presented at ASCO 2013.[7] As a result of a successful Phase Ib/II trials, Phase III trials are currently being initiated.[8]

References

This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.